Related references
Note: Only part of the references are listed.Uncertainty tolerance among experts involved in drug reimbursement recommendations: Qualitative evidence from HTA committees in Canada and Poland
Wieslawa Dominika Wranik et al.
HEALTH POLICY (2021)
Paediatric Medicines in Europe: The Paediatric Regulation-Is It Time for Reform?
Maddalena Toma et al.
FRONTIERS IN MEDICINE (2021)
The new definition of health technology assessment: A milestone in international collaboration
Brian O'Rourke et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2020)
The Methodological Quality and Challenges in Conducting Economic Evaluations of Newborn Screening: A Scoping Review
Pasquale Cacciatore et al.
INTERNATIONAL JOURNAL OF NEONATAL SCREENING (2020)
Does the EU's Paediatric Regulation work for new medicines for children in Denmark, Finland, Norway and Sweden? A cross-sectional study
Pirkko Lepola et al.
BMJ PAEDIATRICS OPEN (2020)
'The problem is small enough, the problem is big enough': a qualitative study of health technology assessment and public policy on drug funding decisions for children
Avram E. Denburg et al.
INTERNATIONAL JOURNAL FOR EQUITY IN HEALTH (2020)
PIH51 EXTRAPOLATION IN GERMAN BENEFIT ASSESSMENT: THE CHALLENGING REQUIREMENTS FOR PEDIATRIC PHARMACEUTICALS
N. Ernst et al.
VALUE IN HEALTH (2019)
Innovations in Pediatric Drug Formulations and Administration Technologies for Low Resource Settings
Stephen E. Gerrard et al.
PHARMACEUTICS (2019)
The impact of parallel regulatory-health technology assessment scientific advice on clinical development. Assessing the uptake of regulatory and health technology assessment recommendations
Giovanni Tafuri et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Patient acceptability, safety and access: A balancing act for selecting age-appropriate oral dosage forms for paediatric and geriatric populations
Jennifer Walsh et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2018)
EXTRAPOLATION OF ADULT DATA FOR PEDIATRIC DRUG BENEFIT ASSESSMENT IN THE AMNOG DOSSIER IN THE LIGHT OF THE NEW AMVSG
P. Stoecker et al.
VALUE IN HEALTH (2017)
Enabling Development of Paediatric Medicines in Europe: 10 Years of the EU Paediatric Regulation
Paolo A. Tomasi et al.
PEDIATRIC DRUGS (2017)
Enhancing the Pediatric Drug Development Framework to Deliver Better Pediatric Therapies Tomorrow
Christina Bucci-Rechtweg
CLINICAL THERAPEUTICS (2017)
How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice
Giovanni Tafuri et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013
Kim Pauwels et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2015)
Values and evidence colliding: health technology assessment in child health
Wendy J. Ungar et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2013)
Decision analysis, economic evaluation, and newborn screening: challenges and opportunities
Lisa A. Prosser et al.
GENETICS IN MEDICINE (2012)
Reimbursement Decisions of the All Wales Medicines Strategy Group Influence of Policy and Clinical and Economic Factors
Warren G. Linley et al.
PHARMACOECONOMICS (2012)
EBM, HTA, and CER: Clearing the Confusion
Bryan R. Luce et al.
MILBANK QUARTERLY (2010)
OUTLOOK Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers
Hans-Georg Eichler et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
QALY weights for neurosensory impairments in pediatric economic evaluations: case studies and a critique
Scott D. Grosse et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2010)
The HTA Core Model: A novel method for producing and reporting health technology assessments
Kristian Lampe et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2009)
NICE Guide to the Methods of Technology Appraisal - Pharmaceutical industry perspective
Julia Earnshaw et al.
PHARMACOECONOMICS (2008)
Measuring health preferences for use in cost-utility and cost-benefit analyses of interventions in children - Theoretical and methodological considerations
Lisa A. Prosser et al.
PHARMACOECONOMICS (2007)
Medicines for children licensed by the European Medicines Agency (EMEA): the balance after 10 years
A. Ceci et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Share Paper
